Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNeck pain is not listed as a recognised side effect of Mounjaro (tirzepatide) in its UK product licence. Most reports of neck discomfort during treatment are likely linked to injection technique, muscle tension, or coincidental causes rather than the medicine itself — though some neck-area symptoms do warrant a closer look. Mounjaro is a prescription-only medicine; any new or persistent pain should be discussed with your prescribing clinician rather than managed alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is no. Neck pain does not appear in the official Mounjaro SmPC side-effect tables, which are drawn from the SURMOUNT clinical trial programme involving thousands of adults with obesity. The side effects that do appear most consistently are gastrointestinal: nausea, loose stools, constipation, reflux and, less commonly, vomiting. Fatigue and headache also feature, but these are distinct from localised neck discomfort.
That said, absence from the formal list does not mean a reported symptom is impossible or imagined. Clinical trials capture statistically significant patterns; rarer or coincidental events sometimes only surface in post-marketing surveillance. The MHRA's Yellow Card scheme exists precisely to collect this kind of real-world signal, and anyone experiencing an unexpected symptom while on any medicine (Mounjaro included) can file a report at yellowcard.mhra.gov.uk.
If you have started Mounjaro recently and noticed neck discomfort you cannot easily explain, the sensible step is to mention it to your prescriber at the next review rather than assume a direct causal link.
A question our prescribers hear most weeks is whether injecting into the upper arm can cause soreness that radiates upward into the neck or shoulder. The honest answer is: yes, it can, though not because of the medicine itself.
Mounjaro is licensed for subcutaneous injection into the abdomen, thigh or upper arm, with site rotation recommended between doses. The upper arm is a smaller target area than the abdomen; if the injection is placed too high, too close to the shoulder joint, or into tense muscle rather than fat, localised discomfort is possible. Some people also tense the arm involuntarily during self-injection, which can leave the surrounding muscles sore for a day or two.
Good technique matters here. Pinching the skin gently, relaxing the arm, and rotating between the three licensed sites can all reduce injection-site reactions. The full technique guidance is set out in the Mounjaro SmPC on the eMC; if you are still struggling with injection comfort after reading it, your prescriber or a pharmacist can walk you through the steps.
For anyone exploring the broader picture of how and where to inject, the Mounjaro overview page covers the basics.
There are specific neck-area symptoms that deserve prompt medical attention, and it is worth knowing what they are before dismissing discomfort as injection-related.
A noticeable lump in the neck, persistent swelling, difficulty swallowing, or a hoarse voice that develops while you are taking a GLP-1 medicine should be assessed by a doctor without delay. This is not a cause for alarm in the vast majority of cases, but the SmPC for tirzepatide and similar medicines includes a precautionary note about medullary thyroid carcinoma (a rare condition) and clinicians are trained to rule it out if relevant symptoms arise. People with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take Mounjaro, which is why the prescribing assessment matters.
You can read more about a lump in the neck on Mounjaro and what to do, as well as the distinction between general neck soreness and symptoms that need faster follow-up. If the concern is skin-related rather than deep tissue, a rash around the neck has its own set of possible explanations worth reviewing.
Some people report neck and shoulder discomfort together, which tends to have more to do with posture and lifestyle shifts than with tirzepatide directly. Significant weight loss, which Mounjaro can support over time, changes the way weight is distributed and can alter how the spine and surrounding muscles are loaded. This is not a reason to avoid treatment; it is a reason to stay active and, where possible, support weight loss with the kind of movement that maintains muscle and joint health.
The NHS patient information page for tirzepatide is a reliable first reference if you are trying to distinguish normal side effects from something that needs clinical input. For a broader view of what the medicine is approved for and the evidence base behind it, the tirzepatide information page sets out the clinical picture clearly.
If cost is part of your thinking as you weigh up treatment, the Mounjaro pricing guide explains how private prescriptions are structured and what to look for in a legitimate provider. Treatment is a clinical decision first; understanding the full picture (including what shoulder and neck symptoms may or may not signal) is part of making that decision well. Whenever you are ready, speak to our prescribers for a same-day clinical review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.